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T cells require costimulatory signals for optimal proliferation, differentiation, 
and survival and thus to induce protective immune responses. Recent data, 
however, show that during chronic lymphocyte choriomeningitis virus (LCMV) 
infection, triggering of the costimulatory receptor CD27 by its ligand CD70 
impedes neutralizing antibody production and leads to viral persistence. Thus, 
while being crucial for the induction of some adaptive effector pathways, 
costimulation may block the development of others. Pathogens may exploit 
this Achilles’ heal to achieve persistence.
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LCMV and CD27
Proper immunity against pathogenic 
infection depends on the well-orches-
trated cooperation of innate and adap-
tive arms of the immune system. In the 
optimal situation, this leads to eradica-
tion of the pathogen and long-term 
memory that protects the host against 
future infection. Toll-like receptors, 
antigen receptors, costimulatory mole-
cules, soluble mediators, and many other 
molecules are all important for the 
  initiation, sustenance, and regulation 
of this intricate process. However, mil-
lions of years of evolutionary pressure 
have also enabled pathogens to develop 
their own sophisticated tools to manip-
ulate the mammalian defense system to 
potentiate their survival and reproduc-
tion in the host. One example of this, 
described in an article by Matter et al. 
in a recent issue of the JEM, suggests a 
new role for the tumor necrosis factor 
(TNF) receptor superfamily member 
CD27 in the clearance of persistent 
LCMV infections (1).
The authors report that CD27 sig-
naling is not benefi  cial for the course of 
the immune response against LCMV, 
but rather has a detrimental eff  ect on 
protective antiviral immunity. This is a 
new and unexpected fi  nding, as CD27 
signaling has so far been regarded as an 
important positive immune regulator 
for the formation and function of eff  ec-
tor and memory T cells. In the absence 
of CD27, for example, the magnitude 
of T and B cell eff  ector responses is re-
duced compared with responses in wild-
type animals (2). Likewise, transgenic 
overexpression of CD70 augments the 
formation of eff   ector T cells leading 
to enhanced protection against non-
immunogenic tumors (3). In the new 
study, however, CD27-defi  cient mice 
were better protected against infection 
with a high dose of LCMV than were 
wild-type mice, because they were able 
to generate virus-specifi  c  neutralizing 
antibodies (nAbs). As shown previ-
ously by this group, the primary cyto-
toxic T cell–dependent response to this 
virus is normal in CD27−/− mice (4). 
The intriguing fi  nding that CD27−/− 
mice developed protective nAbs is ex-
plained by the fact that signals trans-
mitted through CD27 during LCMV 
infection in wild-type mice lead to the 
destruction of splenic lymphoid archi-
tecture. The authors show that LCMV 
infection in wild-type mice, but not in 
CD27−/− mice, causes the destruction 
of germinal centers and the marginal 
zone, which are required for the devel-
opment of nAbs. This destruction is at-
tributed to the production of interferon 
(IFN)-γ and TNF-α by activated CD4+ 
T cells, which depends on the expres-
sion of CD27 on these cells (Fig. 1). 
Blocking CD70 in wild-type mice also 
resulted in the production of nAbs and 
resistance against an otherwise persistent 
strain of LCMV (1). Based on these 
fi  ndings, the authors suggest that block-
ing CD27 signaling could be a novel 
approach for treating clinically relevant 
chronic infections such as HIV and 
hepatitus C virus.
CD27 signals: bad for B cells
The splenic destruction wreaked by 
LCMV infection in mice fi  ts well with 
previous studies on the eff  ects of CD27–
CD70 signaling. Chronic activation of 
CD27 through constitutive expression 
of CD70, for example, leads to the de-
mise of the B cells both in the bone 
marrow and secondary lymphoid organs 
(5). Consistent with this, a conspicuous 
fi  nding in these CD70 transgenic mice 
is the early loss of the splenic marginal 
zone (6), a structure comprising a tight 
organization of specialized macrophages 
and B cells that is required for a protec-
tive immune response against encapsu-
lated bacteria and viruses (7–10).
The spleen is both a major site of 
early LCMV replication and the com-
partment in which cytotoxic T cell and 
antibody responses against the virus are 
initiated—both responses that contrib-
ute to viral clearance (11–13). Although 
it is interesting to speculate that mar-
ginal zone B cells and macrophages are 
uniquely important for the development 
of LCMV-specifi  c nAbs, it is important 
to note that LCMV infection is also ac-
companied by loss of follicular structure 
and germinal center formation (1, 14). 
An intriguing interdependency seems to 
exist between macrophages in the mar-
ginal zone and B cells, as B cell deple-
tion leads to gradual loss of macrophages 
in the marginal zone (6). The organiza-
tion of marginal zone B cells in turn de-
pends on the presence of marginal zone 
macrophages (15). During LCMV in-
fection, follicular B cells remain present, 2406  CD27 IMPEDES HUMORAL RESPONSES | Nolte and van Lier
but both marginal zone macrophages 
and marginal zone B cells disappear, al-
though the cause of their mutual disap-
pearance is not yet known.
During the initial phase of the im-
mune response, antigen presenting cells 
(APCs) up-regulate a large number of 
costimulatory ligands belonging to both 
the immunoglobulin superfamily (most 
prominently the B7 proteins) and the 
TNF family. Taking into account the 
potential plethora of available coacti-
vating ligands, it seems surprising that 
during LCMV infection elimination 
of only the CD27–CD70 interaction 
has such a drastic eff  ect on B cell main-
tenance. Several features of CD27 ex-
pression and function may contribute 
to this apparently dominant role for 
CD27 during LCMV infection. First, 
as pointed out by Croft (16), members 
of the TNF-R family may function in 
a sequential fashion with CD27 being 
activated early in the immune response. 
This role of CD27 early after infection 
might explain why its deletion has such 
a dramatic eff  ect on the course of the an-
tiviral immune response. Second, both 
in vitro and in vivo CD27 signaling has 
a strong eff   ect on the diff  erentiation 
of naive T cells into IFN-γ–secreting 
T helper (Th)1 eff  ector cells. This ef-
fect appears to be due to the ability of 
CD27 to sensitize naive T cells to Th1 
diff   erentiation-inducing signals such 
as interleukin-12 (unpublished data). 
As mentioned previously, IFN-γ is 
known to contribute to the destruction 
of splenic architecture. Third, although 
induction of CD70 expression in vivo 
is hard to demonstrate using pathogens 
such as infl   uenza virus, LCMV was 
found to induce CD70 expression on 
a substantial number of both T and B 
cells during the course of the infection 
(1). It could well be that CD70 expres-
sion is diff  erently regulated in various 
infections. This could depend on the 
tropism of the virus for cells of the im-
mune system and/or recognition of the 
virus by immune cells. Moreover, it 
remains to be clarifi  ed whether other 
costimulatory systems, especially of the 
TNF–TNF receptor pathway, contrib-
ute to LCMV-induced B cell depletion. 
Of special interest is the 4-1BB system, 
as mice that chronically overexpress 4-
1BB ligand display a B cell depletion 
phenotype similar to that seen in CD70 
transgenic mice (17).
Other chronic infections
Protective immunity against LCMV 
and other noncytolytic viruses depends 
on rapid induction of strong Th1/Tc1 
responses and the production of nAbs, 
but these immune defense mechanisms 
are actively circumvented by many vi-
ruses. Some viruses, such as HIV and 
measles, induce a permanent or tran-
sient immunodepression, preventing 
Th1 induction, for example, by sup-
pressing interleukin-12 production 
(18). The induction of Th1/Tc1 im-
mune responses promotes immunity 
against these viruses, probably at least in 
part by activating CD27–CD70 signal-
ing. However, the study by Matter et 
al. raises the possibility that this signal-
ing could also negatively aff  ect the de-
velopment of essential nAbs (1).
Infection with the Leishmania para-
site provides an interesting parallel with 
LCMV infection in that Leishmania 
infections are also associated with the 
destruction of the splenic marginal zone. 
In this system, marginal zone destruc-
tion is caused by a TNF-α–mediated 
decrease in the production of the che-
mokines CCL19 and CCL21, which 
are important for marginal zone main-
tenance (19, 20). CD70 has been shown 
to be up-regulated on dendritic cells 
from  Leishmania-infected mice (21). 
However, whether CD70 expression 
and marginal zone destruction during 
Leishmania infection are causally linked 
is not yet known. It is also unclear 
whether the production of nAbs against 
Leishmania is precluded by the destruc-
tion of the marginal zone. Conspicu-
ously, patients with visceral Leishmaniasis 
are known to suff  er from secondary 
bacterial infections (22) and it would be 
interesting to determine if this could be 
caused by defects in the formation of 
nAbs against these bacteria.
Th1 responses are required for the 
successful eradication of the Leishmania 
pathogen, whereas Th2 responses are 
detrimental and lead to nonhealing 
  disease. It will therefore be interesting 
to investigate whether CD27-mediated 
costimulation, which is benefi  cial  for 
immunity against Leishmania as it prop-
agates Th1/Tc1 responses, can also 
be detrimental caused by inhibition of 
nAb production.
The B cell defects in studies of 
LCMV infection bear a striking re-
semblance to the B cell dysfunctions 
observed in HIV-infected people. Ar-
chitecture of both germinal centers (23, 
24) and splenic marginal zones is dis-
turbed in individuals infected with HIV 
(25). Moreover, the ability to produce 
nAbs is rapidly lost in most people af-
ter HIV infection, but is maintained in 
chimpanzees that harbor the virus but 
do not develop disease (26). Intrigu-
ingly, HIV-infected people, but not 
monkeys, display a chronic activation of 
the immune system, including increased 
expression of CD70 on CD8+ T cells 
(27–29). Combining the mouse, monkey, 
Figure 1.  Strong effector cell formation 
and protective antiviral antibody responses 
may be mutually exclusive during chronic 
viral infection. In this model, strong CD27–
CD70-induced signals trigger robust Th1/Tc1 
effector cell responses, including the production 
of IFN-γ and TNF. If these cytokines are pro-
duced in large quantities, they can induce the 
destruction of lymphoid organ organization and 
thus impair B cell activation. This consequently 
impairs the production of nAbs that are re-
quired to effi  ciently eliminate the pathogen.COMMENTARY
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and human data, it is tempting to sug-
gest that the CD27–CD70 costimulatory 
pathway is instrumental in generating B 
cell dysfunction and in causing the ab-
sence of sustained nAb production after 
HIV infection. It will be interesting to 
investigate if people with long-term 
asymptomatic HIV infections who have 
stable nAb titers diff  er in CD27–CD70 
expression and/or function compared 
with patients that progress to AIDS. 
Moreover, for persistent infections in 
humans, such as HIV and hepatitus C 
virus, specifi  c blockade of the CD27–
CD70 pathway may tip the balance, as 
in chronic LCMV, to favor a protective 
humoral immune response.
Evolutionary pressure
The surprising fi  nding that the absence, 
rather than the presence, of an im-
mune receptor such as CD27 is ben-
efi  cial in the fi  ght against an invading 
pathogen illustrates the challenges with 
which the mammalian immune system 
has to cope. The immune system has 
to fi   nd the optimal balance between 
humoral and cellular responses that is 
suffi   cient in both quality and quantity 
to eradicate the invading pathogen 
without causing immune pathology or 
self-reactivity. Although a strong signal 
through CD27 seems like an appropri-
ate response to viral infection in that it 
enhances Th1/Tc1 responses, it appar-
ently has a major drawback in its ten-
dency to destroy lymphoid organization 
and thus obstruct nAb production. In 
a recent review, Hedrick pointed out 
that during their coevolution, patho-
gens have been at least as creative in 
fi  nding ways to deal with the complex 
adaptive immune system of their hosts 
as their hosts’ immune systems have 
been in fi  nding ways to fend them off   
(30). From this perspective, viruses 
like LCMV may “deliberately” use the 
CD27–CD70 axis to overstimulate one 
arm of the immune response to weaken 
the other. Conversely, it is also possible 
that this is not an evolutionary trick of 
LCMV, but is simply part of the col-
lateral immune damage that is also in-
fl  icted by other pathogens. These issues 
are important to address, as they not 
only provide us with more insight into 
the physiology of the immune system 
and that of the pathogen, but may also 
lead us to new clinical approaches to 
treat infection.
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